舍曲林与帕罗西汀治疗首发抑郁症的24周对照研究(1)
 |
| 第1页 |
参见附件(1926KB，2页)。
[摘要] 目的：比较舍曲林与帕罗西汀治疗首发抑郁症的疗效和安全性。方法：将104例首发抑郁症患者随机分为舍曲林组61例，帕罗西汀组43例，共治疗24周，采用汉密尔顿抑郁量表(HAMD)评定临床疗效，不良反应量表(TESS)评定不良反应。结果：舍曲林组显效率为77%，帕罗西汀组显效率为73%，两组间比较无显著性差异。治疗前后HAMD评分比较两组均有显著性差异，两组间则无显著性差异。两组不良反应TESS评分比较在个别项目上有显著性差异。结论：舍曲林与帕罗西汀治疗首发抑郁症均有良好的疗效，但从不良反应的角度舍曲林可能更适合抑郁症的长期治疗。
[关键词] 舍曲林；帕罗西汀；抑郁症；对照研究
[中图分类号] R749 [文献标识码]A[文章编号]1674-4721(2011)08(b)-038-02
A parallel control study of sertraline and paroxetine in the treatment of first-episode depression for 24 weeks
HUANG Quan
Department of Rehabilitation Families, Guangzhou Red Cross Hospital, Guangdong Province, Guangzhou 510220, China
[Abstract] Objective: To compare the efficacy and safety of sertraline and paroxetine in the treatment of first-episode depression. Methods: 104 patients with first-episode depression were randomly cliviclecl into sertraline group (n=61) and paroxetine group (n=43). In the 24-week treatrnent, the Hamilton Depression Scale (HAMD) ware used to assesse the therapeutic efficacy, and the Treatment Emerget Symptom Scale(TESS) used to evaluate the adverse reactions. Results: Sertraline group was 77% efficiency, the efficiency of paroxetine group was 73%, between the two groups showed no significant difference. HAMD scores were compared before and after treatment were significantly different, between the two groups showed no significant difference. TESS scores between two groups of adverse effects on the individual items were significantly different. Conclusion: Sertraline and paroxetine in the treatment episode depression have good efficacy, but from the perspective of adverse reactions sertraline may be more suitable for long-term treatment of depression.
[Key words] Sertraline; Paroxetine; Depression; Control study
抑郁症为高复发性疾病，抗抑郁药物的治疗策略倡导全程治疗。选择性5-羟色胺再摄取抑制剂是近年临床上广泛应用的抗抑郁药，而舍曲林和帕罗西汀是目前国内使用较多的选择性5-羟色胺再摄取抑制剂(SSRI)[1]，为了探讨舍曲林与帕罗西汀长期治疗首发抑郁症的疗效和安全性的异同，笔者将两者进行对照研究，现报道如下：
1 资料与方法
1.1 一般资料
收集2008年4月～2009年12月来本院门诊就诊的104例患者。入组标准[2]：①符合CCMD-3抑郁发作诊断标准；②首次发病的门诊患者，既往无用药史；③年龄17～75岁，性别不限；④17项汉密尔顿抑郁量表(HAMD17)总分≥17分；⑤患者签署书面知情同意。排除标准：①合并其他精神障碍或药物依赖者；②目前患有严重的躯体疾病或严重药物过敏者；③近期内患过严重感染或经历手术者；④妊娠或哺乳期妇女；⑤参加其他临床药物研究者。
将104例患者随机分为舍曲林组和帕罗西汀组；舍曲林组共61例，男性23例，女性38例；年龄17～72岁，平均(35.62±13.33)岁；病期2～64周，平均(19.00±14.11)周；HAMD17总分17～38分，平均为(25.04±5.21)分。帕罗西汀组共43例，男性20例，女性23例；年龄17～59岁，平均(38.84±12.74)岁；病期2～48周，平均(17 ......
您现在查看是摘要介绍页，详见PDF附件(1926KB，2页)。